Last reviewed · How we verify
Epilim (sodium valproate)
Epilim (generic name: sodium valproate) is a drug developed by Sanofi. It is currently FDA-approved for Absence seizure, Bipolar affective disorder, current episode manic, Epilepsy.
At a glance
| Generic name | sodium valproate |
|---|---|
| Sponsor | Sanofi |
| Target | Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2 |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Absence seizure
- Bipolar affective disorder, current episode manic
- Epilepsy
- Epilepsy characterized by intractable complex partial seizures
- Migraine Prevention
Common side effects
- Somnolence
- Dizziness
- Paresthesia
- Asthenia
- Nausea
- Headache
- Injection site pain
- Taste perversion
- Nausea/vomiting
- Elevated amylase
Serious adverse events
- Hyperammonemia with encephalopathy
- Hallucinations
- Pneumonia
- Abnormal gait
- Injection site reaction
Key clinical trials
- Valproic Acid and Dihydroergotamine as Abortive Therapy in Pediatric Migraine: An Open-Label Randomized Trial. (Phase 2)
- Treatment of Acute Myelogenous Leukemia With the Histone Deacetylase Inhibitor Valproic Cid in Combination With All-trans Retinoic Acid (ATRA) and Low Dose Cytarabine (Phase 1)
- A Double Blind Trial Of Divalproex Sodium For Affective Lability And Alcohol Use Following Traumatic Brain Injury (NA)
- Phase I-II Study of Low Dose CdA Combined With Valproic Acid (VPA) in Previously Treated B-cell Chronic Lymphocytic Leukemia (CLL) Patients (Phase 1)
- A Study of the Safety and Efficacy of Depakote ER Plus an Atypical Antipsychotic Vs. an Atypical Antipsychotic Alone in the Treatment of Schizophrenia (Phase 2)
- Overnight Versus Progressive Conversion of Multiple Daily Dose Enteric-Coated Divalproex to Once-Daily Divalproex Extended Release: Which Strategy is Better Tolerated by Patients With Intellectual Dis (NA)
- Phase I/II Study of Intravenous Infusion of Tetra-o-Methyl Nordihydroguaiaretic Acid (EM-1421) in Subjects With Recurrent High Grade Glioma (Phase 1)
- PLA General Hospital (Phase 1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Epilim CI brief — competitive landscape report
- Epilim updates RSS · CI watch RSS
- Sanofi portfolio CI
Frequently asked questions about Epilim
What is Epilim?
Epilim (sodium valproate) is a pharmaceutical drug developed by Sanofi, indicated for Absence seizure, Bipolar affective disorder, current episode manic, Epilepsy.
What is Epilim used for?
Epilim is indicated for Absence seizure, Bipolar affective disorder, current episode manic, Epilepsy, Epilepsy characterized by intractable complex partial seizures, Migraine Prevention.
Who makes Epilim?
Epilim is developed and marketed by Sanofi (see full Sanofi pipeline at /company/sanofi).
What is the generic name of Epilim?
sodium valproate is the generic (nonproprietary) name of Epilim.
What development phase is Epilim in?
Epilim is FDA-approved (marketed).
What are the side effects of Epilim?
Common side effects of Epilim include Somnolence, Dizziness, Paresthesia, Asthenia, Nausea, Headache. Serious adverse events: Hyperammonemia with encephalopathy, Hallucinations, Pneumonia, Abnormal gait.
What does Epilim target?
Epilim targets Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2.
Related
- Target: All drugs targeting Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2
- Manufacturer: Sanofi — full pipeline
- Therapeutic area: All drugs in Neuroscience
- Indication: Drugs for Absence seizure
- Indication: Drugs for Bipolar affective disorder, current episode manic
- Indication: Drugs for Epilepsy
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing